news

CUPERTINO, Calif., Oct. 12 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the HealthpointCapital Biomaterials Summit. The conference is being held at the Omni Berkshire Place in New York City, NY. Thomas A. Schreck, Chief Financial Officer, will be presenting at the conference on Friday, October 15, 2004 at 1:15 […]

CUPERTINO, Calif., Oct. 5 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the BIO Emerging Company Investor Forum. The conference is being held at The Palace Hotel in San Francisco, CA. Dr. Felix Theeuwes, Chairman and Chief Scientific Officer, will be presenting at the conference on Monday, October 14, 2004

CUPERTINO, Calif., Sep 16, 2004 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the First Annual Merriman Curhan Ford & Co. Investor Summit. The conference is being held at The Mark Hopkins Hotel in San Francisco, CA. Dr. James E. Brown, President and Chief Executive Officer, will be

CUPERTINO, Calif., Aug. 9 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Halpern Capital Summer Growth Stock Conference. The conference is being held at The Campton Place Hotel in San Francisco, CA. Dr. Felix Theeuwes, Chairman and Chief Scientific Officer, will be presenting at the conference on Tuesday, August

CUPERTINO, Calif., Aug 2, 2004 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Adams, Harkness & Hill – 24th Annual Summer Seminar. The conference is being held at the Boston Marriott Long Wharf Hotel. Thomas A. Schreck, Chief Financial Officer, will be presenting at the conference on

CUPERTINO, Calif., July 21 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2004 and an update on its development programs. Our net loss for the three months ended June 30, 2004 was $7.4 million or 14 cents per share, compared to $5.1 million or 10 cents

CUPERTINO, Calif., July 15 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter 2004 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, July 21, 2004 at 4:30 p.m. EST with Jim Brown, President and Chief Executive Officer, Tom

CUPERTINO, Calif., July 6 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced the advancement of its ORADUR(TM) sustained release oral gel-cap technology (formerly referred to as the SABER(TM) oral gel-cap technology) with positive human clinical results for Remoxy(TM). Remoxy is a novel long-acting oral formulation of oxycodone based on DURECT’s ORADUR technology under development by Pain

CUPERTINO, Calif., and VALENCIA, Calif., June 21 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) and NeuroSystec Corporation (“NeuroSystec”), a privately held company located in Valencia, CA, announced today that they have signed an exclusive agreement to develop, market and sell products for the treatment of certain inner ear disorders including chronic tinnitus (ringing in the ears).

CUPERTINO, Calif., May 6 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Rodman & Renshaw Techvest Global Healthcare Conference at 3:30 PM local time (10:30 AM, Eastern Daylight Time) on Wednesday, May 12, 2004 in London, England. Presenting for the company will be Thomas A. Schreck, Chief Financial Officer